Systemic lupus erythematosus – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Wed, 03 Jun 2026 04:05:41 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Systemic lupus erythematosus – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Evaluation of Long-term Safety and Efficacy of Enpatoran in Subacute Cutaneous, Discoid, and Systemic Lupus Erythematosus Post-WILLOW Study Completion https://clinicaltrials.eu/trial/evaluation-of-long-term-safety-and-efficacy-of-enpatoran-in-subacute-cutaneous-discoid-and-systemic-lupus-erythematosus-post-willow-study-completion/ Tue, 02 Jun 2026 09:56:36 +0000 https://clinicaltrials.eu/trial/evaluation-of-long-term-safety-and-efficacy-of-enpatoran-in-subacute-cutaneous-discoid-and-systemic-lupus-erythematosus-post-willow-study-completion/ This clinical trial is focused on studying the effects of a medication called Enpatoran in individuals with certain types of lupus. Lupus is a disease where the immune system attacks healthy tissues, and it can affect the skin, known as cutaneous lupus erythematosus (CLE), or the entire body, known as systemic lupus erythematosus (SLE). The study includes people who have subacute cutaneous lupus erythematosus, discoid lupus erythematosus, and/or systemic lupus erythematosus. The purpose of the study is to evaluate the long-term safety and tolerability of Enpatoran in these participants.

Participants in the study will receive either the medication Enpatoran or a placebo, which looks like the medication but does not contain the active substance. The study is designed to be double-blind, meaning neither the participants nor the researchers know who is receiving the actual medication or the placebo. This helps ensure that the results are not influenced by expectations about the treatment. The study will be conducted over a long period, allowing researchers to gather information on how well the medication is tolerated and any side effects that may occur.

Throughout the study, participants will be monitored for any adverse events, which are unexpected medical problems that occur during treatment. The study will also look at any changes in laboratory tests and heart function, specifically the QT interval, which is a measure of the heart’s electrical activity. This information will help determine the safety profile of Enpatoran for people with lupus. Participants who successfully complete the initial part of the study may have the opportunity to continue in a long-term extension of the study to gather more data on the medication’s effects.

]]> Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus https://clinicaltrials.eu/trial/nipocalimab-in-adults-with-moderate-to-severe-systemic-lupus-erythematosus/ Fri, 29 May 2026 04:02:46 +0000 https://clinicaltrials.eu/trial/nipocalimab-in-adults-with-moderate-to-severe-systemic-lupus-erythematosus/ This study is being done in adults with Systemic Lupus Erythematosus, a long-term disease in which the immune system attacks the body’s own tissues. The treatment being tested is nipocalimab, given as an injection under the skin, compared with placebo. The purpose of the study is to see whether nipocalimab can reduce disease activity in people with this condition.

The study is a Phase 3 trial, which means it is being done in a larger group of people to better understand how well the treatment works and how safe it is. People taking part are assigned by chance to receive either nipocalimab or placebo. The treatment is given over time, and the study team follows participants through the treatment period to observe how the disease changes.

]]> Phase 3 study of ianalumab plus standard drug combination in adults and adolescents with systemic lupus erythematosus https://clinicaltrials.eu/trial/phase-3-study-of-ianalumab-plus-standard-drug-combination-in-adults-and-adolescents-with-systemic-lupus-erythematosus/ Wed, 13 May 2026 05:05:03 +0000 https://clinicaltrials.eu/trial/phase-3-study-of-ianalumab-plus-standard-drug-combination-in-adults-and-adolescents-with-systemic-lupus-erythematosus/ Systemic Lupus Erythematosus is an autoimmune condition in which the body’s immune system mistakenly attacks its own tissues, causing pain, fatigue, skin rashes, and possible damage to organs. Standard‑of‑care therapy usually includes medicines such as corticosteroids (drugs like prednisone that reduce inflammation). In this study the experimental medicine ianalumab is given as a subcutaneous injection (a shot placed under the skin) and is compared with a placebo (an inactive substance).

The purpose of the study is to find out whether adding ianalumab to the usual treatment leads to a better disease response than placebo, using the SRI-4 score at week 60 as the main measure. Participants are randomly assigned to receive either the drug or placebo for about a year, with regular clinic visits for safety checks and disease assessments while they continue their regular medicines; the dose of steroids may be lowered if the disease improves.

Researchers will record how many participants show improvement in disease activity, avoid serious flare‑ups, and are able to reduce steroid use to 5 mg per day or less. They will also monitor for side effects and collect blood samples to check drug levels and any immune reaction against the drug. The study ends after the 60‑week treatment period, followed by a short follow‑up phase.

]]> BI 3000202 in Patients with Moderate to Severe Systemic Lupus Erythematosus https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-bi-3000202-in-patients-with-moderate-to-severe-systemic-lupus-erythematosus/ Thu, 07 May 2026 05:47:16 +0000 https://clinicaltrials.eu/trial/a-study-to-evaluate-the-effectiveness-and-safety-of-bi-3000202-in-patients-with-moderate-to-severe-systemic-lupus-erythematosus/ This clinical trial is studying systemic lupus erythematosus (SLE), a disease in which the immune system attacks the body’s own tissues and can cause swelling, pain, rash, tiredness, and damage to organs. The study will test BI 3000202, an oral film-coated tablet taken by mouth, and compare different dose levels with placebo to see whether the treatment may help people with moderate to severe SLE. The purpose of the study is to evaluate how well and how safely BI 3000202 works in this disease.

In the study, people are assigned by chance to receive one of the dose regimens of BI 3000202 or placebo. The study is double-blind, which means neither the participants nor the study team knows which treatment is given. Treatment is continued for a period of time, and the study follows how the disease changes over several months, including whether symptoms improve and whether steroid medicine can be lowered. The study also looks at whether the disease reaches a lower level of activity, meaning it is calmer and causing fewer problems.

]]> Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Nonbiologic Standard of Care: A Phase 3 Randomized Controlled Trial https://clinicaltrials.eu/trial/efficacy-and-safety-evaluation-of-litifilimab-in-adults-with-active-systemic-lupus-erythematosus-on-nonbiologic-standard-of-care-a-phase-3-randomized-controlled-trial/ Mon, 04 May 2026 08:06:49 +0000 https://clinicaltrials.eu/trial/efficacy-and-safety-evaluation-of-litifilimab-in-adults-with-active-systemic-lupus-erythematosus-on-nonbiologic-standard-of-care-a-phase-3-randomized-controlled-trial/ This clinical trial is focused on studying the effects of a new treatment for Systemic Lupus Erythematosus (SLE), a chronic autoimmune disease where the immune system attacks healthy tissues, causing inflammation and damage to various parts of the body. The treatment being tested is called litifilimab, also known by its code name BIIB059. It is a type of medication known as a recombinant monoclonal antibody, which is administered through an injection under the skin.

The purpose of the study is to evaluate how effective and safe litifilimab is in reducing the activity of SLE in adults who are already receiving standard care for lupus that does not involve biologic treatments. Participants in the study will be randomly assigned to receive either litifilimab or a placebo, which looks like the treatment but does not contain the active ingredient. The study will last for about a year, during which participants will receive regular injections and attend scheduled visits to monitor their health and the effects of the treatment.

Throughout the study, various aspects of the participants’ health will be assessed, including the activity of their lupus symptoms, any changes in their joint health, and their overall quality of life. The study aims to determine if litifilimab can help reduce the symptoms of SLE and improve the well-being of those affected by this condition. Participants will be closely monitored for any side effects or adverse reactions to ensure their safety during the trial.

]]> Efficacy and Safety Evaluation of Litifilimab in Adults with Active Systemic Lupus Erythematosus on Standard Nonbiologic Lupus Care: A Phase 3 Randomized Controlled Trial https://clinicaltrials.eu/trial/efficacy-and-safety-evaluation-of-litifilimab-in-adults-with-active-systemic-lupus-erythematosus-on-standard-nonbiologic-lupus-care-a-phase-3-randomized-controlled-trial/ Mon, 04 May 2026 08:06:46 +0000 https://clinicaltrials.eu/trial/efficacy-and-safety-evaluation-of-litifilimab-in-adults-with-active-systemic-lupus-erythematosus-on-standard-nonbiologic-lupus-care-a-phase-3-randomized-controlled-trial/ This clinical trial is focused on studying the effects of a new treatment for Systemic Lupus Erythematosus (SLE), a chronic autoimmune disease where the immune system attacks healthy tissues, causing inflammation and damage to various parts of the body. The treatment being tested is called BIIB059, also known as litifilimab, which is a type of protein called a recombinant monoclonal antibody. This study aims to evaluate how effective and safe BIIB059 is for adults with active SLE who are already receiving standard care for lupus.

Participants in the study will receive either the BIIB059 treatment or a placebo, which looks like the treatment but does not contain the active ingredient. The study will last for about a year, during which participants will have regular check-ups to monitor their health and the activity of their lupus. The goal is to see if BIIB059 can reduce the symptoms and activity of lupus more effectively than the placebo.

Throughout the study, various aspects of the participants’ health will be assessed, including their response to the treatment and any changes in their lupus symptoms. The study will also track any side effects or adverse events that may occur. This research is important for understanding whether BIIB059 can be a beneficial treatment option for people living with systemic lupus erythematosus.

]]> Study on the Effectiveness and Safety of Deucravacitinib for Patients with Active Systemic Lupus Erythematosus (SLE) https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-deucravacitinib-for-patients-with-active-systemic-lupus-erythematosus-sle-2/ Mon, 04 May 2026 07:50:06 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-deucravacitinib-for-patients-with-active-systemic-lupus-erythematosus-sle-2/ This clinical trial is focused on studying the effects of a medication called deucravacitinib on individuals with Systemic Lupus Erythematosus (SLE). SLE is a chronic autoimmune disease where the immune system mistakenly attacks healthy tissues, causing inflammation and damage to various parts of the body. The medication being tested, deucravacitinib, is taken orally in the form of a film-coated tablet. The study also includes a comparison with a placebo to evaluate the effectiveness and safety of deucravacitinib.

The purpose of this study is to determine if deucravacitinib is more effective than a placebo in treating people with active SLE. Participants in the study will be randomly assigned to receive either deucravacitinib or a placebo. The study will last for a period of 52 weeks, during which participants will be monitored for their response to the treatment. The main goal is to see how many participants achieve a significant improvement in their SLE symptoms by the end of the study period.

Throughout the study, participants will be assessed for changes in their condition, including improvements in joint pain, skin rashes, and overall disease activity. The study will also track any side effects or adverse events that may occur. By the end of the study, researchers hope to gather valuable information on the potential benefits and risks of using deucravacitinib for treating SLE, which could lead to better treatment options for those affected by this condition.

]]> A Study of Idecabtagene Vicleucel CAR-T Cell Therapy for Patients with Autoimmune Diseases That Did Not Respond to B Cell Removal Treatment https://clinicaltrials.eu/trial/a-study-of-idecabtagene-vicleucel-car-t-cell-therapy-for-patients-with-autoimmune-diseases-that-did-not-respond-to-b-cell-removal-treatment/ Thu, 30 Apr 2026 13:08:30 +0000 https://clinicaltrials.eu/trial/a-study-of-idecabtagene-vicleucel-car-t-cell-therapy-for-patients-with-autoimmune-diseases-that-did-not-respond-to-b-cell-removal-treatment/ This study involves patients with severe autoimmune diseases that have not responded well to previous treatments that target B cells. The specific conditions being studied are systemic lupus erythematosus, idiopathic inflammatory myopathy, systemic sclerosis, and primary Sjögren’s syndrome. Autoimmune diseases occur when the body’s immune system mistakenly attacks its own tissues, causing inflammation and damage to various organs. The treatment being tested is idecabtagene vicleucel, also known as Abecma, which is a type of cell therapy where special immune cells called T cells are modified to target a protein called BCMA. This treatment is given as a single intravenous infusion, which means it is delivered directly into a vein.

The purpose of this study is to evaluate the safety of this cell therapy in patients whose autoimmune disease has continued to progress despite receiving treatments that remove B cells from the body. B cells are a type of immune cell that produces antibodies, and in autoimmune diseases, these cells can contribute to the harmful immune response. The study will specifically look at serious side effects including problems with the immune system’s response to the treatment, such as cytokine release syndrome and nervous system complications, as well as damage to organs that does not improve quickly.

During the study, patients will receive the modified T cell treatment and will be closely monitored for any side effects and how their body responds to the therapy. The study will track whether patients experience any severe reactions and how long it takes for these reactions to resolve with appropriate medical care. Patients participating in this study will have already tried multiple standard treatments for their autoimmune disease without success, including at least one treatment specifically designed to eliminate B cells from the body.

]]> Evaluation of Long-Term Safety and Efficacy of Litifilimab in Adults with Active Systemic Lupus Erythematosus: A Phase 3 Multicenter, Randomized, Dose-Blind Study https://clinicaltrials.eu/trial/evaluation-of-long-term-safety-and-efficacy-of-litifilimab-in-adults-with-active-systemic-lupus-erythematosus-a-phase-3-multicenter-randomized-dose-blind-study/ Wed, 29 Apr 2026 15:08:54 +0000 https://clinicaltrials.eu/trial/evaluation-of-long-term-safety-and-efficacy-of-litifilimab-in-adults-with-active-systemic-lupus-erythematosus-a-phase-3-multicenter-randomized-dose-blind-study/ This clinical trial is focused on studying the long-term safety and effectiveness of a treatment called litifilimab, also known by its code name BIIB059. The study is specifically for adults with a condition called Systemic Lupus Erythematosus (SLE), which is an autoimmune disease where the immune system mistakenly attacks healthy tissues in the body. The treatment is administered as an injection under the skin.

The purpose of the study is to evaluate how safe and tolerable litifilimab is over an extended period. Participants in the study will receive either the active treatment or a placebo, which looks like the treatment but does not contain the active ingredient. The study will monitor participants for any side effects and assess the treatment’s impact on their condition over time.

Participants will be involved in the study for a long-term period, during which they will have regular visits to the study center. These visits will include health assessments and monitoring to ensure the safety and effectiveness of the treatment. The study aims to provide valuable information on how well litifilimab works in managing symptoms of Systemic Lupus Erythematosus and its long-term safety profile.

]]> A Study of Obecabtagene Autoleucel for Patients with Severe Lupus and Active Kidney Inflammation Not Responding to Standard Treatment https://clinicaltrials.eu/trial/a-study-of-obecabtagene-autoleucel-for-patients-with-severe-lupus-and-active-kidney-inflammation-not-responding-to-standard-treatment/ Wed, 29 Apr 2026 15:07:53 +0000 https://clinicaltrials.eu/trial/a-study-of-obecabtagene-autoleucel-for-patients-with-severe-lupus-and-active-kidney-inflammation-not-responding-to-standard-treatment/ This study involves people with Systemic Lupus Erythematosus with active lupus nephritis. Systemic Lupus Erythematosus is a long-term condition where the body’s defense system mistakenly attacks its own tissues and organs, causing inflammation and damage in various parts of the body. Lupus nephritis is a serious complication where this attack affects the kidneys, causing inflammation and potentially reducing their ability to filter waste from the blood. The treatment being tested is called obecabtagene autoleucel, also known by its code name AUTO1. This is a specialized treatment made from the patient’s own immune cells called T cells, which are collected and modified in a laboratory to target specific proteins found on certain immune cells. Before receiving this treatment, participants will be given two medications to prepare their body: cyclophosphamide and fludarabine phosphate. These medications help reduce the number of existing immune cells to make room for the modified cells.

The purpose of this study is to evaluate how well obecabtagene autoleucel works and how safe it is for people with severe lupus that has not responded well to other treatments and who have active kidney involvement. The study will measure whether the treatment can help improve kidney function by looking at protein levels in urine and the rate at which the kidneys filter blood, and whether these improvements can be achieved without needing additional rescue treatments.

During the study, participants will first undergo a screening process to determine if they are suitable. If eligible, they will have their T cells collected through a process where blood is drawn from the body, the needed cells are separated, and the remaining blood is returned. These cells are then sent to a facility where they are modified and grown. Before receiving the modified cells back through an infusion into a vein, participants will receive the two preparatory medications over several days. After the infusion of the modified cells, participants will be monitored closely for side effects and will have regular follow-up visits for up to two years. Throughout this time, various tests will be performed to check kidney function, measure disease activity, assess quality of life, monitor for side effects, and track how long the modified cells remain in the body and how they affect the immune system.

]]> Comparing certolizumab pegol and belimumab for patients with moderate or severe systemic lupus erythematosus https://clinicaltrials.eu/trial/comparing-certolizumab-pegol-and-belimumab-for-patients-with-moderate-or-severe-systemic-lupus-erythematosus/ Wed, 29 Apr 2026 15:07:42 +0000 https://clinicaltrials.eu/trial/comparing-certolizumab-pegol-and-belimumab-for-patients-with-moderate-or-severe-systemic-lupus-erythematosus/ This study involves patients with systemic lupus erythematosus, a long-term condition where the body’s defense system mistakenly attacks its own tissues and organs, causing inflammation and damage to various parts of the body such as joints, skin, kidneys, blood cells, brain, heart, and lungs. The study focuses on patients with moderate or severe disease activity, meaning their symptoms are causing noticeable problems in daily life. The treatments being tested are certolizumab pegol and belimumab, both given as injections under the skin. The purpose of the study is to compare how well these two medications work and how safe they are in controlling the disease activity.

During the study, patients will receive either certolizumab pegol or belimumab for up to 52 weeks, which is about one year. Patients may continue taking their usual medications for lupus, such as pills to control the immune system or reduce inflammation, as long as the doses remain stable. The study will measure several aspects of the disease, including overall disease activity using special scoring systems that look at different body organs and symptoms, the ability to reduce the dose of steroid medications that patients may be taking, changes in joint pain and swelling, skin problems, tiredness levels, and overall quality of life. Doctors will regularly assess how active the disease is and whether patients are experiencing any side effects from the treatment.

The main goal is to see what percentage of patients show meaningful improvement in their disease after one year of treatment, defined as a significant reduction in disease activity scores without any new or worsening symptoms in major organs. The study will also look at whether patients can reduce their steroid doses while keeping their disease under control, since long-term use of steroids can cause unwanted effects. Additionally, researchers will track how patients feel in terms of energy levels, physical functioning, and overall well-being throughout the treatment period.

]]> Study of B Cell Response to Tetanus Toxoid Vaccination in Patients with Systemic Sclerosis, Systemic Lupus Erythematosus, and Rheumatoid Arthritis https://clinicaltrials.eu/trial/study-of-b-cell-response-to-tetanus-toxoid-vaccination-in-patients-with-systemic-sclerosis-systemic-lupus-erythematosus-and-rheumatoid-arthritis/ Wed, 29 Apr 2026 15:07:27 +0000 https://clinicaltrials.eu/trial/study-of-b-cell-response-to-tetanus-toxoid-vaccination-in-patients-with-systemic-sclerosis-systemic-lupus-erythematosus-and-rheumatoid-arthritis/ This clinical trial focuses on understanding immune system responses in patients with autoimmune diseases, specifically Systemic Sclerosis, Systemic Lupus Erythematosus, and Rheumatoid Arthritis. These conditions occur when the body’s immune system mistakenly attacks its own tissues. The study will use a Tetanus Toxoid vaccine, which is commonly used to protect against tetanus infection, to examine how the immune system responds in people with these conditions compared to healthy individuals.

The study aims to examine how specific immune cells called B cells respond to the tetanus vaccine in people with autoimmune diseases. Participants will receive a single booster shot of the tetanus vaccine as a suspension for injection into the muscle. The amount given will be 0.5 milliliters, which is a standard vaccine dose.

During the study, researchers will collect blood samples at different times to observe how the immune system responds to the vaccine. They will look at special immune cells and proteins in the blood before and after vaccination. This will help them understand the differences between how the immune system works in people with autoimmune diseases compared to people without these conditions.

]]> Study of Telitacicept compared to placebo in adults with moderate to severe systemic lupus erythematosus https://clinicaltrials.eu/trial/study-of-telitacicept-compared-to-placebo-in-adults-with-moderate-to-severe-systemic-lupus-erythematosus/ Wed, 29 Apr 2026 15:07:14 +0000 https://clinicaltrials.eu/trial/study-of-telitacicept-compared-to-placebo-in-adults-with-moderate-to-severe-systemic-lupus-erythematosus/ This study focuses on patients with Systemic Lupus Erythematosus, an autoimmune disease where the body’s immune system attacks its own tissues, causing inflammation and damage to various organs. The study will test a medication called telitacicept, which is given as an injection under the skin using a pre-filled syringe, alongside standard treatments for lupus.

The research aims to determine how well telitacicept works in treating moderate to severe forms of lupus compared to placebo. The study will last 52 weeks, during which participants will receive weekly injections of either telitacicept or placebo. Two different doses of telitacicept will be tested: 160 mg and 240 mg.

Throughout the study, participants will continue their regular lupus medications, which may include glucocorticoids, antimalarial drugs, or other medications that suppress the immune system. The study will monitor how well the treatment works and check for any side effects. Participants will have regular check-ups to assess their lupus symptoms and overall health during the treatment period.

]]> Study of Mosunetuzumab Treatment in Patients with Systemic Lupus Erythematosus with or without Lupus Nephritis https://clinicaltrials.eu/trial/study-of-mosunetuzumab-treatment-in-patients-with-systemic-lupus-erythematosus-with-or-without-lupus-nephritis/ Wed, 29 Apr 2026 15:07:05 +0000 https://clinicaltrials.eu/trial/study-of-mosunetuzumab-treatment-in-patients-with-systemic-lupus-erythematosus-with-or-without-lupus-nephritis/ This study focuses on Systemic Lupus Erythematosus (SLE), an autoimmune disease where the body’s immune system attacks its own tissues, with some patients also having Lupus Nephritis, which affects the kidneys. The study will test a medicine called mosunetuzumab, which is a specialized antibody given by subcutaneous injection (injection under the skin).

The purpose of this research is to evaluate how well mosunetuzumab works in helping patients achieve disease remission. The study will include two groups of patients: those who have SLE with kidney involvement (Lupus Nephritis) and those who have SLE without kidney problems. Both groups will receive treatment with mosunetuzumab, and their health will be monitored for changes in disease activity and overall well-being.

Throughout the study, doctors will track various aspects of the participants’ health, including changes in disease symptoms, kidney function, fatigue levels, and how well the medication is tolerated. They will also monitor the levels of certain proteins in the blood that indicate disease activity and check how the body processes the medication. The study will last several years to thoroughly evaluate the long-term effects of the treatment.

]]> Study of CC-97540 CD19-targeted CAR T cells in patients with systemic lupus erythematosus who did not respond to previous immunosuppressive treatment https://clinicaltrials.eu/trial/study-of-cc-97540-cd19-targeted-car-t-cells-in-patients-with-systemic-lupus-erythematosus-who-did-not-respond-to-previous-immunosuppressive-treatment/ Wed, 29 Apr 2026 15:06:57 +0000 https://clinicaltrials.eu/trial/study-of-cc-97540-cd19-targeted-car-t-cells-in-patients-with-systemic-lupus-erythematosus-who-did-not-respond-to-previous-immunosuppressive-treatment/ This clinical trial focuses on evaluating a treatment for patients with Systemic Lupus Erythematosus (SLE) and Lupus Nephritis, which are autoimmune conditions where the body’s immune system attacks its own tissues. The main treatment being studied is called CD19-Targeted NEX-T CAR T (also known as CC-97540 or BMS-986353), which consists of specially modified immune cells designed to target specific cells in the body.

Before receiving the main treatment, patients will undergo preparation with three medications: cyclophosphamide, fludarabine, and tocilizumab. These medications are given through intravenous infusion to prepare the body for the CAR T cell treatment. The purpose of this study is to evaluate how effective CC-97540 is in treating patients with SLE who haven’t responded well enough to previous treatments with steroids and other immune-suppressing medications.

The treatment process involves collecting the patient’s own immune cells, modifying them in a laboratory to target specific disease-causing cells, and then returning them to the patient through an intravenous infusion. After the treatment, patients will be monitored to see if their disease symptoms improve and if they can achieve remission without needing other medications.

]]> Study of RSV vaccines Arexvy and Abrysvo in patients with inflammatory rheumatic diseases receiving anti-rheumatic treatments https://clinicaltrials.eu/trial/study-of-rsv-vaccines-arexvy-and-abrysvo-in-patients-with-inflammatory-rheumatic-diseases-receiving-anti-rheumatic-treatments/ Wed, 29 Apr 2026 15:06:33 +0000 https://clinicaltrials.eu/trial/study-of-rsv-vaccines-arexvy-and-abrysvo-in-patients-with-inflammatory-rheumatic-diseases-receiving-anti-rheumatic-treatments/ This study focuses on patients with Inflammatory Rheumatic Disease who receive various treatments including disease modifying anti-rheumatic drugs (DMARDs) such as methotrexate, and different biological treatments like anti-TNF, anti-IL6r, anti-CD20, and JAK-inhibitors. The study will evaluate how these treatments affect the body’s response to Respiratory Syncytial Virus (RSV) vaccination.

Two different RSV vaccines will be used in the study: Arexvy and Abrysvo. Both vaccines are given as a single injection into the muscle. The purpose is to determine if the medications used to treat inflammatory rheumatic disease affect how well the body develops protection after receiving the RSV vaccine.

Participants will receive one dose of the RSV vaccine and will have blood samples taken before and after vaccination to measure their body’s immune response. The study will also monitor any side effects that may occur after vaccination. This information will help healthcare providers better understand how these treatments influence vaccine effectiveness in patients with inflammatory rheumatic disease.

]]> Study of Blinatumomab Treatment in Patients with Systemic Lupus Erythematosus, Systemic Sclerosis, or Granulomatosis with Polyangiitis: Safety and Effectiveness Evaluation https://clinicaltrials.eu/trial/study-of-blinatumomab-in-patients-with-autoimmune-diseases-systemic-lupus-erythematosus-systemic-sclerosis-or-granulomatosis-with-polyangiitis/ Wed, 29 Apr 2026 15:06:21 +0000 https://clinicaltrials.eu/trial/study-of-blinatumomab-in-patients-with-autoimmune-diseases-systemic-lupus-erythematosus-systemic-sclerosis-or-granulomatosis-with-polyangiitis/ This clinical study focuses on evaluating a medication called Blinatumomab in treating three different autoimmune conditions: Systemic Lupus Erythematosus (a disease that can affect multiple organs and tissues), Systemic Sclerosis (a condition causing hardening of the skin and internal organs), and Granulomatosis with Polyangiitis (an inflammation of blood vessels that affects various body organs). These conditions are all driven by abnormal activity of B-cells, which are part of the immune system.

The purpose of this research is to determine if Blinatumomab is safe and well-tolerated by patients with these conditions. The medication is given through an intravenous infusion, which means it is delivered directly into a vein. The treatment involves receiving the medicine over a period of 10 days, with a specific daily amount that has been carefully determined for safety.

During the study, patients will be monitored for 52 weeks (one year) to check how their body responds to the treatment. The research team will track any side effects that may occur and measure how well the treatment works by checking blood tests for specific antibodies and evaluating disease symptoms. This is an open-label study, which means all participants will receive the active medication.

]]> Study on the Safety of CNTY-101 and Aldesleukin for Patients with Active Autoimmune Diseases: Lupus, Scleroderma, and Myositis https://clinicaltrials.eu/trial/study-on-the-safety-of-cnty-101-and-aldesleukin-for-patients-with-active-autoimmune-diseases-lupus-scleroderma-and-myositis/ Wed, 29 Apr 2026 15:04:48 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-cnty-101-and-aldesleukin-for-patients-with-active-autoimmune-diseases-lupus-scleroderma-and-myositis/ This clinical trial is focused on studying certain autoimmune diseases, which are conditions where the body’s immune system mistakenly attacks its own tissues. The diseases being studied include Idiopathic Inflammatory Myositis, Systemic Lupus Erythematosus, and Systemic Sclerosis. The trial will test a new treatment called CNTY-101, which is a type of cell therapy. This treatment involves using specially modified cells to help reduce the activity of the immune system that is causing harm. The study will also use a medication called Aldesleukin, which is given as an injection under the skin.

The purpose of the study is to assess the safety of CNTY-101 in people with active autoimmune diseases driven by B-cells, which are a type of immune cell. Participants in the study will receive the treatment through an intravenous infusion, which means it will be delivered directly into the bloodstream. The study will monitor participants over time to see how they respond to the treatment and to check for any side effects.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how the treatment affects their condition. The study aims to provide valuable insights into the potential benefits and risks of using CNTY-101 for treating these autoimmune diseases. This research could lead to new ways of managing these conditions in the future.

]]> Study on the Effectiveness of Telitacicept for Adults with Moderate to Severe Systemic Lupus Erythematosus https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-telitacicept-for-adults-with-moderate-to-severe-systemic-lupus-erythematosus/ Wed, 29 Apr 2026 15:02:41 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-of-telitacicept-for-adults-with-moderate-to-severe-systemic-lupus-erythematosus/ This clinical trial is focused on studying the effects of a treatment called Telitacicept for people with Systemic Lupus Erythematosus (SLE)</b), which is a condition where the immune system mistakenly attacks healthy tissues in the body. The study aims to evaluate how effective and safe Telitacicept is for patients who have moderate to severe symptoms of this disease and have not responded well to standard treatments. Participants in the study will receive either the Telitacicept injection or a matching placebo, which is a substance with no active medication.

The study will last for about 52 weeks, during which participants will receive regular injections. The treatment is administered through a pre-filled syringe as a subcutaneous injection, meaning it is injected under the skin. Throughout the study, participants will be monitored to see how their symptoms change and to check for any side effects. The goal is to see if Telitacicept can help reduce the symptoms of SLE and improve the quality of life for those affected by this condition.

Participants will be assessed at various points during the study to determine their response to the treatment. The main focus is on the proportion of patients who show improvement in their symptoms by the end of the study. Additionally, the study will look at other factors, such as the ability to reduce the use of other medications like prednisone, which is often used to manage SLE symptoms. The safety of the treatment will also be closely monitored to ensure it is well-tolerated by participants.

]]> Study on the Effects of Rituximab and Obinutuzumab in Patients with Systemic Lupus Erythematosus (SLE) https://clinicaltrials.eu/trial/study-on-the-effects-of-rituximab-and-obinutuzumab-in-patients-with-systemic-lupus-erythematosus-sle/ Wed, 29 Apr 2026 15:01:58 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-rituximab-and-obinutuzumab-in-patients-with-systemic-lupus-erythematosus-sle/ This clinical trial is focused on studying the effects of two medications, Rituximab and Obinutuzumab, on patients with Systemic Lupus Erythematosus (SLE). SLE is a chronic autoimmune disease where the immune system mistakenly attacks healthy tissues, causing inflammation and damage to various parts of the body, including the skin, joints, and kidneys. The purpose of this study is to explore how these medications affect certain immune cells in the blood and tissues of SLE patients.

Participants in the study will receive either Rituximab or Obinutuzumab, both of which are administered through an intravenous infusion, meaning they are given directly into a vein. The study will last for up to 52 weeks, during which time researchers will monitor changes in specific immune cells, particularly a type of white blood cell called B cells, in the blood and lymph nodes. The study aims to identify changes in these cells and how they relate to the progression and treatment response of SLE.

By examining these effects, the study hopes to find new markers that can help tailor treatments to individual patients, a concept known as personalized medicine. This could lead to better management of SLE by predicting how patients will respond to these treatments. The study will also look at how these changes in immune cells correlate with improvements in the symptoms and severity of SLE, providing valuable insights into the disease and its treatment.

]]> Study on the Effects of Belimumab for Patients with Systemic Lupus Erythematosus (SLE) https://clinicaltrials.eu/trial/study-on-the-effects-of-belimumab-for-patients-with-systemic-lupus-erythematosus-sle/ Wed, 29 Apr 2026 15:01:57 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-belimumab-for-patients-with-systemic-lupus-erythematosus-sle/ This clinical trial is focused on studying the effects of a medication called belimumab on patients with Systemic Lupus Erythematosus (SLE), a disease where the immune system attacks the body’s own tissues, causing inflammation and damage. The purpose of the study is to explore how belimumab affects certain immune cells and tissues in the body, particularly in the lymph nodes and joints.

Participants in the study will receive belimumab, which is administered as a solution for injection using a pre-filled pen. Some participants will receive other treatments for comparison. The study will observe changes in specific immune cells in the blood and lymph nodes over time, aiming to understand how these changes relate to the disease and the response to belimumab treatment. This information could help identify new ways to personalize treatment for SLE patients in the future.

The study will take place over a period of time, with regular monitoring of participants to assess the effects of the treatment. The goal is to gather valuable information that could lead to better treatment strategies for SLE, potentially improving outcomes for those affected by this condition.

]]> Long-term Safety Study of AUTO4 and Rituximab in Patients with Potential Malignancy Treated with Autologous CAR T Cell Therapy https://clinicaltrials.eu/trial/long-term-safety-study-of-auto4-and-rituximab-in-patients-with-potential-malignancy-treated-with-autologous-car-t-cell-therapy/ Wed, 29 Apr 2026 15:01:40 +0000 https://clinicaltrials.eu/trial/long-term-safety-study-of-auto4-and-rituximab-in-patients-with-potential-malignancy-treated-with-autologous-car-t-cell-therapy/ This clinical trial focuses on the long-term follow-up of patients who have previously been treated with a special type of therapy called CAR T cell therapy. This therapy involves using a patient’s own T cells, which are a type of immune cell, that have been genetically modified to better fight certain diseases. The diseases being studied in this trial are potential cancers that may develop in patients who have received this therapy. The main goal of the study is to monitor the long-term safety of these treatments.

The study involves two specific treatments: AUTO1 and AUTO4, both of which are types of CAR T cell therapies. These treatments are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein. Another treatment involved in the study is rituximab, known by the brand name MabThera, which is also given as an infusion. Rituximab is a medication that targets specific proteins on the surface of certain cells and is used in various conditions, including some types of cancer.

During the course of the study, participants will be monitored for any serious side effects related to the CAR T cell therapy, the development of new cancers, and other specific health events of interest. The study will also track overall survival rates and the duration of any supportive care needed. Additionally, researchers will look for any remaining genetic material from the therapy in the blood and check for any potential causes of new cancers. This follow-up will continue for up to 15 years after the initial CAR T cell therapy infusion.

]]> Study on the Safety of MB-CART19.1 for Patients with Active Systemic Lupus Erythematosus, Systemic Sclerosis, or Dermatomyositis/Polymyositis https://clinicaltrials.eu/trial/study-on-the-safety-of-mb-cart19-1-for-patients-with-active-systemic-lupus-erythematosus-systemic-sclerosis-or-dermatomyositis-polymyositis/ Wed, 29 Apr 2026 15:00:36 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-of-mb-cart19-1-for-patients-with-active-systemic-lupus-erythematosus-systemic-sclerosis-or-dermatomyositis-polymyositis/ This clinical trial is focused on studying the effects of a new treatment for certain autoimmune diseases. The diseases being studied are Systemic Lupus Erythematosus, Systemic Sclerosis, and Dermatomyositis/Polymyositis. These are conditions where the body’s immune system mistakenly attacks its own tissues. The treatment being tested is called MB-CART19.1, which involves using a patient’s own T-cells that have been modified to better target and fight the disease. These T-cells are changed using a special process involving a lentiviral vector to express a chimeric antigen receptor directed against a protein called CD19.

The purpose of the study is to assess the safety of this new treatment in patients with active forms of these autoimmune diseases. Participants in the study will receive the treatment through an infusion, which means it will be administered directly into the bloodstream. The study will monitor participants for any side effects or reactions to the treatment, particularly focusing on any signs of Cytokine Release Syndrome and CAR T cell Associated Neurotoxicity Syndrome within the first few weeks after receiving the treatment.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how the treatment affects their condition. The study aims to provide valuable insights into the potential of this innovative therapy for managing these challenging autoimmune diseases. The trial is expected to continue until 2026, allowing researchers to collect comprehensive data on the treatment’s safety and effects over time.

]]> Study on the Effects of Belimumab and Rituximab for Patients with Severe Systemic Lupus Erythematosus https://clinicaltrials.eu/trial/study-on-the-effects-of-belimumab-and-rituximab-for-patients-with-severe-systemic-lupus-erythematosus/ Wed, 29 Apr 2026 15:00:06 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-belimumab-and-rituximab-for-patients-with-severe-systemic-lupus-erythematosus/ This clinical trial is focused on studying a disease called Systemic Lupus Erythematosus (SLE), which is a condition where the immune system mistakenly attacks healthy tissues in the body. The study is testing a combination of two treatments: Benlysta (belimumab) and Truxima (rituximab). These medications are designed to help manage the symptoms of SLE by targeting specific parts of the immune system. Benlysta is given as an injection under the skin, while Truxima is administered through an infusion into a vein.

The purpose of the study is to see if the combination of Benlysta and Truxima is more effective than the usual treatments, which include medications like mycophenolate and steroids. Participants in the study will receive either the combination treatment or the standard treatment. The study will last for about two years, during which time the effectiveness of the treatments will be monitored. This includes looking at how well the treatments reduce the activity of the disease and how they affect the immune system over time.

Throughout the study, researchers will also keep track of any side effects or safety concerns related to the treatments. The goal is to find out if the combination of Benlysta and Truxima can provide a better long-term outcome for people with severe SLE compared to the standard treatments. This research could lead to improved treatment options for those living with this challenging condition.

]]> Study on the Effects of Ianalumab in Adults with Rheumatoid Arthritis, Systemic Lupus Erythematosus, or Sjögren’s Disease https://clinicaltrials.eu/trial/study-on-the-effects-of-ianalumab-in-adults-with-rheumatoid-arthritis-systemic-lupus-erythematosus-or-sjogrens-disease/ Wed, 29 Apr 2026 14:59:22 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-ianalumab-in-adults-with-rheumatoid-arthritis-systemic-lupus-erythematosus-or-sjogrens-disease/ This clinical trial is focused on studying the effects of a medication called ianalumab in adults with autoimmune diseases, specifically Rheumatoid Arthritis, Systemic Lupus Erythematosus, and Sjögren’s Disease. Autoimmune diseases occur when the body’s immune system mistakenly attacks its own tissues. The study aims to compare how the body processes ianalumab when given in different forms, such as a pre-filled syringe or an auto-injector. Ianalumab is a type of protein-based medication designed to help manage these conditions by targeting specific parts of the immune system.

Participants in the study will receive ianalumab through subcutaneous injections, which means the medication is administered under the skin. The study will take place over a period of time, allowing researchers to observe how the medication is absorbed and processed by the body. The goal is to ensure that the different forms of administering ianalumab are equally effective and safe for patients. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of ianalumab.

In addition to ianalumab, the study will also involve other medications such as emtricitabine, tenofovir disoproxil, tenofovir alafenamide, and entecavir, which are typically used to manage viral infections. These medications will be administered orally, meaning they are taken by mouth. The study will monitor various health indicators, including any side effects, to ensure the safety and effectiveness of the treatments. The overall purpose is to gather information that could lead to better treatment options for people with these autoimmune diseases.

]]> Study on the Safety and Effectiveness of CABA-201, Fludarabine Phosphate, and Cyclophosphamide in Patients with Active Systemic Lupus Erythematosus https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-caba-201-fludarabine-phosphate-and-cyclophosphamide-in-patients-with-active-systemic-lupus-erythematosus/ Wed, 29 Apr 2026 14:59:19 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effectiveness-of-caba-201-fludarabine-phosphate-and-cyclophosphamide-in-patients-with-active-systemic-lupus-erythematosus/ This clinical trial is focused on studying the treatment of Systemic Lupus Erythematosus (SLE), a chronic autoimmune disorder. In SLE, the body’s immune system mistakenly attacks its own tissues, leading to inflammation and damage in various organs. A severe form of this disease, known as lupus nephritis, affects the kidneys and can lead to significant health issues. The study will use a treatment called CABA-201, which involves a type of cell therapy using specially modified immune cells known as CD19-specific Chimeric Antigen Receptor T cells. These cells are designed to target and destroy specific immune cells that are involved in the disease process.

The purpose of the study is to evaluate the safety and tolerability of CABA-201 in individuals with active SLE over a period of 28 days. Participants will receive the treatment through an infusion, which is a method of delivering medication directly into the bloodstream. The study will monitor participants for any side effects and changes in their condition during and after the treatment. This will help researchers understand how well the treatment works and how safe it is for patients with SLE.

Throughout the study, participants will undergo regular health checks, including physical examinations and laboratory tests, to assess their response to the treatment. The study aims to gather information on the effectiveness of CABA-201 in reducing the symptoms of SLE and improving the overall health of participants. This research could potentially lead to new treatment options for people living with this challenging autoimmune disorder.

]]> Study on Long-Term Safety of Cenerimod for Adults with Moderate-to-Severe Systemic Lupus Erythematosus https://clinicaltrials.eu/trial/study-on-long-term-safety-of-cenerimod-for-adults-with-moderate-to-severe-systemic-lupus-erythematosus/ Wed, 29 Apr 2026 14:59:14 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-of-cenerimod-for-adults-with-moderate-to-severe-systemic-lupus-erythematosus/ This clinical trial is focused on studying the long-term safety and tolerability of a medication called cenerimod in adults with systemic lupus erythematosus (SLE). SLE is a chronic autoimmune disease where the body’s immune system mistakenly attacks healthy tissues, causing inflammation and damage to various parts of the body. The medication being tested, cenerimod, is taken as a film-coated tablet and is intended to be used alongside other ongoing treatments for SLE.

The purpose of this study is to evaluate how safe and well-tolerated cenerimod is when used over an extended period. Participants in the study will take a daily dose of 4 milligrams of cenerimod. The study is designed as an open-label, single-arm extension, meaning all participants will receive cenerimod, and there will be no comparison group receiving a placebo. The study will monitor participants for any side effects or adverse events that may occur during the treatment period.

Participants will be involved in the study for a maximum of 36 months, during which they will have regular check-ups to assess their health and any potential side effects from the medication. The study aims to gather information on the long-term effects of cenerimod to ensure it is a safe option for people living with systemic lupus erythematosus. This information will help healthcare providers make informed decisions about the use of cenerimod in treating SLE.

]]> Study on the Effects of Rapcabtagene Autoleucel in Patients with Systemic Lupus Erythematosus and Active, Refractory Lupus Nephritis https://clinicaltrials.eu/trial/study-on-the-effects-of-rapcabtagene-autoleucel-in-patients-with-systemic-lupus-erythematosus-and-active-refractory-lupus-nephritis/ Wed, 29 Apr 2026 14:58:52 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-rapcabtagene-autoleucel-in-patients-with-systemic-lupus-erythematosus-and-active-refractory-lupus-nephritis/ This clinical trial is focused on studying the effects of a treatment called rapcabtagene autoleucel in people with a condition known as systemic lupus erythematosus (SLE), which is a disease where the immune system attacks the body’s own tissues. Specifically, the study targets those with a severe form of SLE that affects the kidneys, called lupus nephritis. The purpose of the study is to compare the effectiveness and safety of rapcabtagene autoleucel against the standard treatments currently used for this condition.

Participants in the study will receive either rapcabtagene autoleucel or one of the standard treatments, which may include medications like cyclophosphamide, voclosporin, belimumab, rituximab, mycophenolate mofetil, tacrolimus, or fludarabine phosphate. Rapcabtagene autoleucel is a type of cell therapy that involves modifying a person’s own immune cells to better fight the disease. The study will last for about a year, during which participants will be monitored to see how well the treatment works and to check for any side effects.

The study is designed to help researchers understand if rapcabtagene autoleucel can provide better outcomes for patients with lupus nephritis compared to the current standard treatments. Participants will be assessed for improvements in their condition and any changes in their health over the course of the study. This research aims to find more effective ways to manage and treat lupus nephritis, potentially offering new hope for those affected by this challenging condition.

]]> Study of Obexelimab Treatment for Adults with Systemic Lupus Erythematosus (SLE) https://clinicaltrials.eu/trial/study-on-the-effects-of-obexelimab-for-patients-with-systemic-lupus-erythematosus/ Wed, 29 Apr 2026 14:58:33 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-obexelimab-for-patients-with-systemic-lupus-erythematosus/ This clinical trial is studying a treatment for Systemic Lupus Erythematosus, an autoimmune disease where the body’s immune system attacks its own tissues. The study will test a new medication called obexelimab to determine if it can reduce disease activity in people with this condition. The medication will be given through subcutaneous injection, which means it is injected under the skin.

The main purpose of this research is to evaluate how well obexelimab works compared to placebo in reducing lupus disease activity. During the study, participants will also receive standard lupus treatments, which may include antimalarial medications, corticosteroids like prednisolone, or other medications that suppress the immune system.

The study will last 24 weeks, during which participants will receive either obexelimab or placebo injections. Throughout the study, doctors will monitor various aspects of the disease, including skin symptoms, joint problems, and overall disease activity. They will also track how the treatment affects participants’ fatigue levels and general well-being. The maximum daily dose of obexelimab will be 250 mg, with a total maximum dose of 6000 mg over the course of treatment.

]]> Study on Steroid Withdrawal in Systemic Lupus Erythematosus Patients Using Prednisone https://clinicaltrials.eu/trial/study-on-steroid-withdrawal-in-systemic-lupus-erythematosus-patients-using-prednisone/ Wed, 29 Apr 2026 14:57:38 +0000 https://clinicaltrials.eu/trial/study-on-steroid-withdrawal-in-systemic-lupus-erythematosus-patients-using-prednisone/ This clinical trial is focused on studying Systemic Lupus Erythematosus (SLE), a disease where the immune system mistakenly attacks healthy tissues in the body. The study is examining the effects of withdrawing a medication called Prednisone, which is a type of drug known as a glucocorticoid. Glucocorticoids are often used to reduce inflammation and suppress the immune system. In this trial, participants will either stop taking Prednisone or continue with a low dose to see if stopping the medication is just as effective as continuing it for maintaining a stable condition.

The purpose of the study is to determine if patients with SLE, who are already on standard treatment and have their disease under control, can safely stop taking glucocorticoids without worsening their condition. Participants will be monitored over a period of 36 months to see if they can maintain a stable state without the medication. The study will involve regular check-ups to ensure the health and safety of the participants.

Throughout the study, the main focus will be on whether patients can maintain a stable condition known as low disease activity state (LLDAS) after stopping glucocorticoids. The trial will also look at how many patients remain in remission, meaning their disease is not active, at different points during the study. This research aims to provide valuable information on the long-term management of SLE and the potential benefits of reducing medication use.

]]> Study on MK-6194 for Adults with Systemic Lupus Erythematosus https://clinicaltrials.eu/trial/study-on-mk-6194-for-adults-with-systemic-lupus-erythematosus/ Wed, 29 Apr 2026 14:56:46 +0000 https://clinicaltrials.eu/trial/study-on-mk-6194-for-adults-with-systemic-lupus-erythematosus/ This clinical trial is focused on studying the effects of a new treatment for Systemic Lupus Erythematosus (SLE), a chronic autoimmune disease where the body’s immune system mistakenly attacks healthy tissue. The treatment being tested is called MK-6194, which is administered as a solution for injection. The study will compare the effects of MK-6194 to a placebo to determine its effectiveness and safety in treating SLE.

The purpose of the study is to evaluate how well MK-6194 works in reducing the symptoms of SLE and to assess its safety for patients. Participants in the study will receive either MK-6194 or a placebo and will be monitored over a period of time to observe any changes in their condition. The study will last for a total of 104 weeks, with key assessments taking place at weeks 28 and 52. During this time, researchers will look at various indicators of disease activity and any side effects experienced by participants.

Throughout the study, participants will be closely observed to ensure their safety and to gather data on how MK-6194 affects their SLE symptoms. The study aims to provide valuable information on whether MK-6194 can be a beneficial treatment option for people living with SLE, potentially improving their quality of life by managing the disease more effectively.

]]> Study of Belimumab for Children with Systemic Lupus Erythematosus (SLE) https://clinicaltrials.eu/trial/study-of-belimumab-for-children-with-systemic-lupus-erythematosus-sle/ Wed, 29 Apr 2026 14:47:44 +0000 https://clinicaltrials.eu/trial/study-of-belimumab-for-children-with-systemic-lupus-erythematosus-sle-2/ This clinical trial is focused on studying a disease called Systemic Lupus Erythematosus (SLE), which is a condition where the immune system mistakenly attacks healthy tissues in the body. The study involves a treatment called belimumab, which is a type of medication known as a monoclonal antibody. This medication is designed to help manage the symptoms of SLE by targeting specific proteins in the immune system that contribute to the disease.

The purpose of this study is to understand how belimumab works in children with SLE when it is given as an injection under the skin. Participants in the study will receive the medication in a pre-filled pen, which is a device that makes it easier to administer the injection. The study will also include a group of participants who will receive a placebo, which is a substance with no active medication, to compare the effects of the treatment. The study will last for about a year, during which participants will have regular check-ups to monitor their health and the effects of the treatment.

Throughout the study, researchers will collect information on how the body processes belimumab and how safe it is for use in children with SLE. They will also look at how the treatment affects certain markers in the blood that are related to the disease. This information will help doctors understand more about the potential benefits and risks of using belimumab in young patients with SLE, and could lead to improved treatment options in the future.

]]> Study on the Effectiveness and Safety of Obinutuzumab for Patients with Systemic Lupus Erythematosus https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-obinutuzumab-for-patients-with-systemic-lupus-erythematosus/ Wed, 29 Apr 2026 14:47:35 +0000 https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-obinutuzumab-for-patients-with-systemic-lupus-erythematosus/ This clinical trial is focused on studying the effects of a medication called Obinutuzumab in patients with a condition known as Systemic Lupus Erythematosus (SLE). SLE is an autoimmune disease, which means the body’s immune system mistakenly attacks its own tissues, causing inflammation and damage to various parts of the body. The study aims to evaluate how effective and safe Obinutuzumab is for people with SLE. Participants in the study will receive either Obinutuzumab or a placebo, which is a substance with no active medication.

The study will be conducted over a period of time, during which participants will receive the treatment through an intravenous infusion, meaning the medication is given directly into a vein. The study will monitor the participants’ response to the treatment, looking at various health indicators to determine if the medication helps reduce the symptoms of SLE. The goal is to see if Obinutuzumab can help more people achieve a better state of health compared to those who do not receive the active medication.

Throughout the study, participants will be regularly assessed to track their progress and any changes in their condition. The study will also keep an eye on any side effects or adverse events that may occur. By the end of the study, researchers hope to gather enough information to understand the potential benefits and risks of using Obinutuzumab for treating Systemic Lupus Erythematosus.

]]> Study of Anifrolumab for Adults with Moderate-to-Severe Systemic Lupus Erythematosus https://clinicaltrials.eu/trial/study-of-anifrolumab-for-adults-with-moderate-to-severe-systemic-lupus-erythematosus/ Wed, 29 Apr 2026 14:29:42 +0000 https://clinicaltrials.eu/trial/study-of-anifrolumab-for-adults-with-moderate-to-severe-systemic-lupus-erythematosus/ This clinical trial is focused on studying the effects of a treatment for Systemic Lupus Erythematosus (SLE), a condition where the immune system mistakenly attacks healthy tissues in the body, causing inflammation and damage to various organs. The treatment being tested is called Anifrolumab, which is administered as a solution for injection under the skin. Anifrolumab is being compared to a placebo to evaluate its effectiveness and safety in reducing the overall disease activity in adults with moderate-to-severe SLE.

The purpose of the study is to assess how well Anifrolumab works in managing the symptoms of SLE. Participants in the study will receive either Anifrolumab or a placebo through a prefilled syringe designed for subcutaneous use, meaning it is injected just under the skin. The study will follow participants over a period to monitor their response to the treatment and any changes in their condition.

Throughout the study, researchers will observe the participants to determine if Anifrolumab can help reduce the activity of SLE and improve the patients’ quality of life. The study aims to provide valuable information on the potential benefits of Anifrolumab for individuals living with this challenging autoimmune disease.

]]> Study on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus https://clinicaltrials.eu/trial/study-on-long-term-safety-of-ianalumab-for-patients-with-systemic-lupus-erythematosus/ Wed, 29 Apr 2026 14:29:37 +0000 https://clinicaltrials.eu/trial/study-on-long-term-safety-of-ianalumab-for-patients-with-systemic-lupus-erythematosus/ This clinical trial is focused on studying the long-term safety and tolerability of a treatment called ianalumab in patients with Systemic Lupus Erythematosus (SLE). SLE is a chronic autoimmune disease where the body’s immune system mistakenly attacks healthy tissue, causing inflammation and damage to various parts of the body. The study involves administering ianalumab, which is given as a solution for injection under the skin, either monthly or quarterly. The purpose of the study is to evaluate how safe and well-tolerated ianalumab is over an extended period.

Participants in the study may receive ianalumab or a placebo. The study will monitor participants for any side effects or adverse reactions that may occur during the treatment period. The study will also assess the overall health and condition of the participants over time, including any changes in their disease symptoms and the use of other medications, such as oral corticosteroids, which are often used to reduce inflammation in SLE.

The study is designed to last for several years, allowing researchers to gather comprehensive data on the long-term effects of ianalumab in treating SLE. Participants will be regularly evaluated to track their progress and any changes in their condition. This research aims to provide valuable insights into the potential benefits and risks of using ianalumab as a treatment option for individuals living with Systemic Lupus Erythematosus.

]]> Study on the Safety and Effects of YTB323, Fludarabine Phosphate, and Tocilizumab in Patients with Severe, Refractory Systemic Lupus Erythematosus https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-ytb323-fludarabine-phosphate-and-tocilizumab-in-patients-with-severe-refractory-systemic-lupus-erythematosus/ Wed, 29 Apr 2026 14:29:09 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-ytb323-fludarabine-phosphate-and-tocilizumab-in-patients-with-severe-refractory-systemic-lupus-erythematosus/ This clinical trial is focused on studying a condition called Systemic Lupus Erythematosus (SLE), which is a disease where the immune system mistakenly attacks healthy tissues in the body. The study specifically looks at a severe form of this disease, known as severe, refractory Systemic Lupus Erythematosus (srSLE), which does not respond well to standard treatments. The main treatment being tested in this study is called YTB323, which is a type of cell therapy. This treatment involves using a patient’s own immune cells, which are modified to better target and fight the disease. The study also involves other medications, including Fludarabine Phosphate, Cyclophosphamide, and Tocilizumab, which are used to prepare the body for the main treatment or manage side effects.

The purpose of the study is to assess the safety of YTB323 in patients with srSLE. Participants will receive the treatment through an infusion, which means it is delivered directly into the bloodstream. The study will monitor how the treatment affects the body over time, including any side effects and how the immune cells behave after being modified. The study will also look at how well the treatment works in reducing the symptoms of srSLE.

Throughout the study, participants will have regular check-ups to monitor their health and the effects of the treatment. This includes checking vital signs, conducting blood tests, and evaluating any changes in the disease. The study aims to provide valuable information on the potential benefits and risks of using YTB323 for treating severe cases of SLE that have not responded to other treatments.

]]> Study of Enpatoran in Adults with Systemic Lupus Erythematosus (SLE) and Cutaneous Lupus Erythematosus (CLE) https://clinicaltrials.eu/trial/study-on-enpatoran-for-patients-with-systemic-lupus-erythematosus-and-cutaneous-lupus-erythematosus/ Wed, 29 Apr 2026 14:28:33 +0000 https://clinicaltrials.eu/trial/study-on-enpatoran-for-patients-with-systemic-lupus-erythematosus-and-cutaneous-lupus-erythematosus/ This clinical study focuses on Systemic Lupus Erythematosus (SLE) and Cutaneous Lupus Erythematosus (CLE), which are autoimmune conditions where the body’s immune system attacks its own tissues. SLE can affect multiple organs throughout the body, while CLE primarily affects the skin, causing rashes and lesions. The study will test a new medication called enpatoran in patients who are already receiving standard treatments for lupus.

The purpose of this research is to evaluate how different doses of enpatoran work in reducing disease activity, particularly focusing on skin symptoms and overall disease control. During the study, participants will receive either enpatoran tablets or placebo in addition to their current lupus medications. The study will track changes in participants’ symptoms and overall health for up to 24 months.

This is a Phase 2 study, which means the medication has already been tested for basic safety in humans, and researchers are now studying how well it works at different doses. The study is designed to be double-blind, which means neither the participants nor the healthcare providers will know who is receiving enpatoran or placebo during the study period.

]]> Study on Ianalumab for Patients with Systemic Lupus Erythematosus https://clinicaltrials.eu/trial/study-on-ianalumab-for-patients-with-systemic-lupus-erythematosus/ Wed, 29 Apr 2026 14:28:18 +0000 https://clinicaltrials.eu/trial/study-on-ianalumab-for-patients-with-systemic-lupus-erythematosus/ This clinical trial is focused on studying a disease called Systemic Lupus Erythematosus (SLE), which is an autoimmune condition where the body’s immune system mistakenly attacks its own tissues. The study is testing a treatment called ianalumab, also known by its code name VAY736. This treatment is given as a solution for injection using a pre-filled syringe. The purpose of the study is to evaluate the effectiveness, safety, and tolerability of ianalumab when used alongside standard treatments for SLE.

Participants in the study will receive either ianalumab or a placebo, which is a substance with no active medication. The study will last for about 60 weeks, during which participants will receive monthly injections. The goal is to see if ianalumab can help improve the condition of patients with SLE by achieving a specific response known as the Systemic Lupus Erythematosus Responder Index (SRI-4) by the end of the study period.

Throughout the study, researchers will monitor participants for any changes in their condition, including the occurrence of flare-ups, which are periods when symptoms worsen. They will also track the use of corticosteroids, a type of medication often used to manage SLE symptoms, to see if ianalumab can help reduce the need for these drugs. The study will also assess the overall health and well-being of participants, including any side effects they may experience. The information gathered will help determine if ianalumab is a beneficial addition to the current standard of care for people with SLE.

]]> Study on Belimumab for Children with Systemic Lupus Erythematosus (SLE) https://clinicaltrials.eu/trial/study-on-belimumab-for-children-with-systemic-lupus-erythematosus-sle/ Wed, 29 Apr 2026 14:28:09 +0000 https://clinicaltrials.eu/trial/study-on-belimumab-for-children-with-systemic-lupus-erythematosus-sle/ This clinical trial is focused on studying a disease called Systemic Lupus Erythematosus (SLE), which is a condition where the immune system mistakenly attacks healthy tissues in the body. The trial is testing a treatment called Belimumab, which is a type of medication known as a monoclonal antibody. This medication is designed to target and block a specific protein in the body that is involved in the immune response, potentially helping to reduce the symptoms of SLE. The study will also use a placebo for comparison purposes.

The purpose of the study is to evaluate how effective and safe Belimumab is for children with Systemic Lupus Erythematosus. Participants in the study will receive either the medication or a placebo, along with their usual treatment for SLE. The study will last for a period of time, during which participants will have regular check-ups to monitor their health and the effects of the treatment. The study aims to understand how the medication affects the body, its safety, and its impact on the quality of life of the participants.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to gather information on how Belimumab works in children with Systemic Lupus Erythematosus. The study will help determine if this treatment can be a beneficial addition to the standard therapy for managing SLE in pediatric patients. The results will contribute to a better understanding of the treatment options available for this condition.

]]> Study on the Effects of Abacavir and Lamivudine in Patients with Systemic Lupus Erythematosus with Low Disease Activity https://clinicaltrials.eu/trial/study-on-the-effects-of-abacavir-and-lamivudine-in-patients-with-systemic-lupus-erythematosus-with-low-disease-activity/ Wed, 29 Apr 2026 14:27:14 +0000 https://clinicaltrials.eu/trial/study-on-the-effects-of-abacavir-and-lamivudine-in-patients-with-systemic-lupus-erythematosus-with-low-disease-activity/ This clinical trial is focused on studying the effects of a treatment for Systemic Lupus Erythematosus, commonly known as lupus. Lupus is an autoimmune disease where the body’s immune system mistakenly attacks healthy tissues. The treatment being tested is a combination of two medications, Abacavir and Lamivudine, which are typically used to treat viral infections. In this study, they are being used to see if they can help manage lupus by affecting certain immune system signals known as the interferon signature.

The purpose of the study is to evaluate how well the Abacavir/Lamivudine combination works when added to the standard care for lupus over a period of six months. Participants will be randomly assigned to receive either the medication combination or a placebo, in addition to their usual treatment. The study will monitor changes in the interferon signature, which is a pattern of gene activity linked to lupus, to see if the treatment can reduce it. The study will also look at other factors, such as the maintenance of low disease activity, the number of lupus relapses, and the use of other medications like corticosteroids.

Participants in the study will take the medication orally in the form of film-coated tablets. The trial will last for a total of six months, during which time the participants’ health and response to the treatment will be closely monitored. The study aims to provide new insights into the potential benefits of using Abacavir and Lamivudine for treating lupus, which could lead to improved management of the disease in the future.

]]>